progesterone-receptor positive breast cancer
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0060077
Name progesterone-receptor positive breast cancer
Definition A breast cancer that is characterized by the presence of progesterone receptors.
Source DiseaseOntology.org
Alt Ids
Xrefs
Path disease disease of cellular proliferation cancer organ system cancer breast cancer progesterone-receptor positive breast cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA H1047R Everolimus progesterone-receptor positive breast cancer predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Completed USA 0
NCT00759642 Phase II Lapatinib Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy Terminated USA 0
NCT01177397 Phase Ib/II Onatasertib Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed USA | GBR | FRA | ESP 0
NCT01857193 Phase Ib/II Everolimus + Exemestane + Ribociclib Exemestane + Ribociclib Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Completed USA | FRA | ESP | BEL 1
NCT01872260 Phase I Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CHE | AUS 1
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Completed USA 0
NCT02035813 Phase II Ribociclib Eribulin DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). Completed DEU 0
NCT02115282 Phase III Exemestane + Goserelin Entinostat + Exemestane + Goserelin Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Active, not recruiting USA 1
NCT02918084 Phase III Exemestane Anastrozole Letrozole CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (GIM10-CONSENT) Active, not recruiting ITA 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | HUN | GBR | DNK | CAN | BEL | AUS 2
NCT04054752 Phase I NT-I7 Vaccine Response With NT-I7 Withdrawn USA 0
NCT04064359 Phase I MEN1309 Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors Recruiting USA | GRC | FRA | ESP | BEL 0
NCT04197999 Phase I GMI-1359 A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer Terminated USA 0
NCT04256941 Phase II Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study Terminated USA 0
NCT04305834 Phase II Abemaciclib Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer Recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Active, not recruiting USA | GBR 0
NCT04557449 Phase I Letrozole + PF-07220060 Fulvestrant + PF-07220060 Enzalutamide + PF-07220060 PF-07220060 Midazolam + PF-07220060 Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4i) Active, not recruiting USA | SVK | GBR | CZE | ARG 3
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Terminated USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT04789668 Phase Ib/II Bintrafusp alfa + Pimasertib Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases Terminated USA 0
NCT05417594 Phase Ib/II AZD9574 + Trastuzumab deruxtecan AZD9574 + Datopotamab deruxtecan AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | SWE | GBR | ESP | DEU | AUS 1
NCT05538572 Phase I PRT3645 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors Completed USA 1
NCT05565417 Phase Ib/II Fruquintinib + IMT-009 IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas Active, not recruiting USA 0
NCT05627960 Phase I AG01 First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies Recruiting USA 0
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | GBR | ESP | BEL 0
NCT05768139 Phase Ib/II Exemestane + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Anastrozole + Ribociclib + STX-478 Anastrozole + Palbociclib + STX-478 Letrozole + Ribociclib + STX-478 Letrozole + Palbociclib + STX-478 Fulvestrant + Ribociclib + STX-478 Fulvestrant + Palbociclib + STX-478 Fulvestrant + STX-478 STX-478 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) Recruiting USA | NLD | ITA | IRL | FRA | ESP | DEU | BEL 1
NCT06018337 Phase III Nab-paclitaxel Paclitaxel DB-1303 Capecitabine A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) Active, not recruiting USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG 3
NCT06224673 Phase II ARX-788 ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer Not yet recruiting USA 0
NCT06263543 Phase II Sacituzumab govitecan-hziy Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC (SERIES) Recruiting USA 0
NCT06486883 Phase II Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Exemestane + Ribociclib Anastrozole + Ribociclib Exemestane + Palbociclib Letrozole + Ribociclib Abemaciclib + Exemestane Letrozole + Palbociclib Fulvestrant + Ribociclib Trastuzumab deruxtecan Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (PONTIAC) Recruiting ITA | FRA | ESP | DEU 1
NCT06545331 Phase I Pembrolizumab + XB010 XB010 Study of XB010 in Subjects With Solid Tumors Recruiting USA | GBR 0
NCT06680596 Phase II Trastuzumab deruxtecan Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy (SAFIR3LibHERty) Enrolling by invitation FRA 0
NCT06999187 Phase I DR-0202 A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas Recruiting USA 0
NCT07030712 Phase I MK-8294 A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) Recruiting USA | NLD | ISR 0
NCT07112053 Phase II Capecitabine + STEMVAC STEMVAC A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Recruiting USA 0
NCT07137416 Phase I CX-5461 + Trastuzumab deruxtecan Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Recruiting USA 0
NCT07205822 Phase III Datopotamab deruxtecan A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer (TB06) Recruiting USA | ITA | FRA | ESP 2
NCT07460752 Phase II Goserelin Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients Not yet recruiting USA 0